



# Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM's Board of Directors

Tuesday, November 10, 2015 - 08:00am

**Montreal, November 10, 2015.** – The Chairman of the Board, Dr. Léon Gosselin, and the President and CEO of CQDM, Dr. Diane Gosselin, are pleased to announce the appointment of Dr. Uwe Schoenbeck, Chief Scientific Officer, External Research & Development Innovation (ERDI), Pfizer Inc., as member of CQDM's Board of Directors.

Pfizer is a founding partner in CQDM and has played an integral role in supporting the mission of the consortium – to help develop breakthrough tools and technologies that facilitate potential new drug discovery and development. Through CQDM's unique approach, both public and private stakeholders in the consortium share the costs and the results of important biopharmaceutical research.

Dr. Schoenbeck leads Pfizer's ERDI team, which seeks to identify and establish relationships with external collaborators that have complementary areas of expertise in order to help drive the discovery and development of potential new therapies that address areas of high unmet medical need. He is also a member of Pfizer's Worldwide R&D leadership team and sits on Pfizer's Senior Leadership Council.

"It is with great enthusiasm that we welcome Uwe Schoenbeck on our Board of Directors. With his extensive experience in worldwide research and development, as well as external partnerships in the biopharmaceutical industry, Uwe will certainly enrich our discussions and greatly contribute to the development of CQDM. We are more than delighted and honored to have Uwe on board and look forward to continuing our fruitful and valuable collaboration with Pfizer," said Dr. Gosselin.

"I am honored to be part of CQDM's Board of Directors, and hope that my industry perspective can provide guidance to the organization and prove a valuable addition," said

Dr. Schoenbeck. “I look forward to continuing a mutually beneficial collaboration, through which scientists from both Pfizer and CQDM come together with a common goal of finding capabilities that will help lead to potential innovative new therapies for patients.”

Dr. Schoenbeck received his degree from the University of Kiel in Germany and completed postdoctoral training in the Division of Cardiovascular Medicine at Brigham & Women’s Hospital at Harvard before joining as a faculty member. Dr. Schoenbeck has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles. He also reviewed articles and book chapters, as well as abstracts with particular contributions in areas such as molecular and cell biology, cardiovascular research, immunology and metabolism.

**About CQDM** CQDM is a pharma-based consortium active in early research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery. Unique in the world, CQDM’s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM also provides a common meeting ground where academia, governments, and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. CQDM receives financial support from Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Janssen, Novartis Pharma Canada, Sanofi Canada, as well as from Quebec’s Ministry of Economy, Innovation and Exports (MEIE) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information, visit us at [www.cqdm.org](http://www.cqdm.org).

-30-

Source: Julie Martineau Senior Director, Communications and Corporate Development  
CQDM Tel.: (514) 766-6661, ext. 2198 [jmartineau@cqdm.org](mailto:jmartineau@cqdm.org) [www.cqdm.org](http://www.cqdm.org)